Pharmacyclics Given Consensus Rating of “Buy” by Analysts (NASDAQ:PCYC)
Pharmacyclics (NASDAQ:PCYC) has earned an average recommendation of “Buy” from the nineteen analysts that are currently covering the company, American Banking & Market News reports. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $155.33.
In other Pharmacyclics news, Insider Heow Tan sold 10,000 shares of Pharmacyclics stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $123.58, for a total value of $1,235,800.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Pharmacyclics (NASDAQ:PCYC) opened at 122.26 on Wednesday. Pharmacyclics has a 52-week low of $82.51 and a 52-week high of $154.89. The stock has a 50-day moving average of $106.0 and a 200-day moving average of $108.3. The company has a market cap of $9.202 billion and a P/E ratio of 110.97.
Pharmacyclics (NASDAQ:PCYC) last posted its quarterly earnings results on Thursday, July 31st. The company reported ($0.26) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.23) by $0.03. The company had revenue of $113.00 million for the quarter, compared to the consensus estimate of $95.88 million. During the same quarter last year, the company posted $0.25 earnings per share. Pharmacyclics’s revenue was up 106.6% compared to the same quarter last year. Analysts expect that Pharmacyclics will post $0.36 EPS for the current fiscal year.
PCYC has been the subject of a number of recent research reports. Analysts at William Blair raised their price target on shares of Pharmacyclics from $150.00 to $180.00 in a research note on Tuesday, August 5th. They now have an “outperform” rating on the stock. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of Pharmacyclics in a research note on Friday, August 1st. They now have a $180.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Pharmacyclics in a research note on Friday, August 1st. They now have a $152.00 price target on the stock, up previously from $150.00.
Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.